New hope for ovarian cancer: drug combo trial seeks best dose

NCT ID NCT07059845

First seen Nov 03, 2025 · Last updated May 07, 2026 · Updated 28 times

Summary

This study tests an experimental drug called mirvetuximab soravtansine (MIRV) combined with either bevacizumab or carboplatin in people with a specific type of ovarian cancer. About 320 participants will receive different doses to find the safest and most effective treatment. The goal is to control the disease and improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Austin Hospital /ID# 276534

    RECRUITING

    Melbourne, Victoria, 3084, Australia

  • Burnside War Memorial Hospital /ID# 277602

    RECRUITING

    Adelaide, South Australia, 5065, Australia

  • Icon Cancer Centre Hobart /ID# 277688

    RECRUITING

    Hobart, Tasmania, 7000, Australia

  • Icon Cancer Centre Wesley /ID# 277199

    RECRUITING

    Auchenflower, Queensland, 4066, Australia

  • Korea University Guro Hospital /ID# 276194

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 08308, South Korea

  • Monash Health - Monash Medical Centre /ID# 276984

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • Samsung Medical Center /ID# 276261

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Seoul National University Hospital /ID# 276182

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • St. George Private Hospital /ID# 276570

    RECRUITING

    Kogarah, New South Wales, 2217, Australia

  • Yonsei University Health System Severance Hospital /ID# 276266

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 03722, South Korea

Conditions

Explore the condition pages connected to this study.